Role of the Tumor Microenvironment in Mature B-cell Lymphoid Malignancies

Overview

Journal Haematologica

Specialty Hematology

Date 2016 May 2

PMID 27132279

Citations 52

Authors

Nathan H Fowler

Chan Yoon Cheah

Randy D Gascoyne

John Gribben

Sattva S Neelapu

Paolo Ghia

Catherine Bollard

Stephen Ansell

Michael Curran

Wyndham H Wilson

Susan OBrien

Cliona Grant

Richard Little

Thorsten Zenz

Loretta J Nastoupil

Kieron Dunleavy

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.

Citing Articles

In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?.

Mattioda C, Voena C, Ciardelli G, Mattu C Cells. 2025; 14(1.

PMID: 39791739 PMC: 11720277. DOI: 10.3390/cells14010038.

Multi-Omics Profiling Unveils the Complexity and Dynamics of Immune Infiltrates in Intrahepatic Cholangiocarcinoma.

Li X, Wang Y, Guan R, Sheng N, Zhang S Biology (Basel). 2024; 13(10).

PMID: 39452125 PMC: 11504529. DOI: 10.3390/biology13100816.

EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.

Sherif M, Schafer H, Scharf S, van Oostendorp V, Sadeghi Shoreh Deli A, Loth A Br J Haematol. 2024; 205(6):2327-2337.

PMID: 39355919 PMC: 11637725. DOI: 10.1111/bjh.19778.

Tumor microenvironment as a complex milieu driving cancer progression: a mini review.

Li Z, Li J, Bai X, Huang X, Wang Q Clin Transl Oncol. 2024; .

PMID: 39342061 DOI: 10.1007/s12094-024-03697-w.

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.

Bakhtiyaridovvombaygi M, Yazdanparast S, Kheyrandish S, Safdari S, Amiri Samani F, Sohani M Biomark Res. 2024; 12(1):66.

PMID: 39020411 PMC: 11253502. DOI: 10.1186/s40364-024-00610-z.

References

Burger J, Keating M, Wierda W, Hartmann E, Hoellenriegel J, Rosin N . Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014; 15(10):1090-9. PMC: 4174348. DOI: 10.1016/S1470-2045(14)70335-3. View

Ahmadzadeh M, Johnson L, Heemskerk B, Wunderlich J, Dudley M, White D . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-44. PMC: 2927090. DOI: 10.1182/blood-2008-12-195792. View

Dotti G, Savoldo B, Pule M, Straathof K, Biagi E, Yvon E . Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005; 105(12):4677-84. PMC: 1895003. DOI: 10.1182/blood-2004-08-3337. View

Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D . lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008; 14(14):4650-7. DOI: 10.1158/1078-0432.CCR-07-4405. View

Pegram H, Lee J, Hayman E, Imperato G, Tedder T, Sadelain M . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-41. PMC: 3359735. DOI: 10.1182/blood-2011-12-400044. View

Brusa D, Serra S, Coscia M, Rossi D, DArena G, Laurenti L . The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6):953-63. PMC: 3669453. DOI: 10.3324/haematol.2012.077537. View

Twa D, Mottok A, Chan F, Ben-Neriah S, Woolcock B, Tan K . Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol. 2015; 236(2):136-41. DOI: 10.1002/path.4522. View

Pulford K, Sipos A, Cordell J, Stross W, Mason D . Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol. 1990; 2(10):973-80. DOI: 10.1093/intimm/2.10.973. View

Ramsay A, Clear A, Kelly G, Fatah R, Matthews J, MacDougall F . Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009; 114(21):4713-20. PMC: 2780306. DOI: 10.1182/blood-2009-04-217687. View

10.

Shaffer 3rd A, Young R, Staudt L . Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012; 30:565-610. PMC: 7478144. DOI: 10.1146/annurev-immunol-020711-075027. View

11.

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

12.

Liu Y, Sattarzadeh A, Diepstra A, Visser L, van den Berg A . The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol. 2013; 24:15-22. DOI: 10.1016/j.semcancer.2013.07.002. View

13.

Farinha P, Masoudi H, Skinnider B, Shumansky K, Spinelli J, Gill K . Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106(6):2169-74. DOI: 10.1182/blood-2005-04-1565. View

14.

Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2010; 117(2):563-74. PMC: 3031480. DOI: 10.1182/blood-2010-05-284984. View

15.

Eaton D, Gilham D, ONeill A, Hawkins R . Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. 2002; 9(8):527-35. DOI: 10.1038/sj.gt.3301685. View

16.

Kohrt H, Sagiv-Barfi I, Rafiq S, Herman S, Butchar J, Cheney C . Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014; 123(12):1957-60. PMC: 3962169. DOI: 10.1182/blood-2014-01-547869. View

17.

Perez-Galan P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2010; 117(1):26-38. PMC: 3037747. DOI: 10.1182/blood-2010-04-189977. View

18.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

19.

Gopal A, Kahl B, de Vos S, Wagner-Johnston N, Schuster S, Jurczak W . PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370(11):1008-18. PMC: 4039496. DOI: 10.1056/NEJMoa1314583. View

20.

Allegra D, Bilan V, Garding A, Dohner H, Stilgenbauer S, Kuchenbauer F . Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia. 2013; 28(1):98-107. DOI: 10.1038/leu.2013.246. View